{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:38:00Z","timestamp":1787164680283,"version":"build-2736575974"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.jocn.2019.12.063","type":"journal-article","created":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T17:39:00Z","timestamp":1579196340000},"page":"144-149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Metastatic melanoma: Surgical treatment of brain metastases \u2013 Analysis of 110 patients"],"prefix":"10.1016","volume":"73","author":[{"given":"Frances Anne","family":"McHugh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien Yew","family":"Kow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Falkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Heppner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Bok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Schweder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2019.12.063_b0005","unstructured":"New Cancer Registrations 2015. 2017 14\/12\/2017 [cited 2018 14\/11]; Available from: https:\/\/www.health.govt.nz\/publication\/new-cancer-registrations-2015."},{"key":"10.1016\/j.jocn.2019.12.063_b0010","doi-asserted-by":"crossref","unstructured":"Melanoma Guidelines. 2018 23\/7\/18 [cited 2018 14\/11]; Available from: https:\/\/www.health.govt.nz\/your-health\/conditions-and-treatments\/diseases-and-illnesses\/melanoma.","DOI":"10.12968\/eqhe.2018.40.23"},{"key":"10.1016\/j.jocn.2019.12.063_b0015","unstructured":"Service., N.C.R.a.A., Routes to diagnosis of cancer by stage 2012-2013 workbook. London: NCRAS; 2016. 2016, National Cancer Registration and Analysis Service http:\/\/www.ncin.org.uk\/publications\/routes_to_diagnosis."},{"issue":"8","key":"10.1016\/j.jocn.2019.12.063_b0020","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/cncr.25634","article-title":"Prognostic factors for survival in melanoma patients with brain metastases","volume":"117","author":"Davies","year":"2011","journal-title":"Cancer"},{"issue":"14","key":"10.1016\/j.jocn.2019.12.063_b0025","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","article-title":"Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System","volume":"22","author":"Barnholtz-Sloan","year":"2004","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jocn.2019.12.063_b0030","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ctrv.2004.05.001","article-title":"The treatment of brain metastases in melanoma patients","volume":"30","author":"Bafaloukos","year":"2004","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jocn.2019.12.063_b0035","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ctrv.2016.03.003","article-title":"Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: a systematic review","volume":"45","author":"Spagnolo","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.jocn.2019.12.063_b0040","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JOP.2016.011882","article-title":"Management of brain metastases in patients with melanoma","volume":"12","author":"Chukwueke","year":"2016","journal-title":"J Oncol Pract"},{"issue":"2","key":"10.1016\/j.jocn.2019.12.063_b0045","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1215\/15228517-2007-058","article-title":"Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features","volume":"10","author":"Raizer","year":"2008","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.jocn.2019.12.063_b0050","doi-asserted-by":"crossref","first-page":"11934","DOI":"10.1038\/s41598-018-30417-6","article-title":"Inhibiting the CD8(+) T cell infiltration in the tumor microenvironment after radiotherapy is an important mechanism of radioresistance","volume":"8","author":"Chen","year":"2018","journal-title":"Sci Rep"},{"issue":"17","key":"10.1016\/j.jocn.2019.12.063_b0055","doi-asserted-by":"crossref","first-page":"8352","DOI":"10.1158\/0008-5472.CAN-06-0533","article-title":"Tumor cell radiosensitivity is a major determinant of tumor response to radiation","volume":"66","author":"Gerweck","year":"2006","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.jocn.2019.12.063_b0060","first-page":"830","article-title":"The radiation response of human malignant melanoma cells grown in vitro","volume":"31","author":"Barranco","year":"1971","journal-title":"Cancer Res"},{"key":"10.1016\/j.jocn.2019.12.063_b0065","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.critrevonc.2016.12.003","article-title":"Melanoma: last call for radiotherapy","volume":"110","author":"Espenel","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"10.1016\/j.jocn.2019.12.063_b0070","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3892\/or.2012.2139","article-title":"Stereotactic radiosurgery for the treatment of melanoma and renal cell carcinoma brain metastases","volume":"29","author":"Lwu","year":"2013","journal-title":"Oncol Rep"},{"key":"10.1016\/j.jocn.2019.12.063_b0075","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1748-717X-6-48","article-title":"Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis","volume":"6","author":"Minniti","year":"2011","journal-title":"Radiat Oncol"},{"issue":"2","key":"10.1016\/j.jocn.2019.12.063_b0080","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/CCO.0000000000000057","article-title":"The role of systemic therapies in the management of melanoma brain metastases","volume":"26","author":"Lyle","year":"2014","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.jocn.2019.12.063_b0085","doi-asserted-by":"crossref","first-page":"393","DOI":"10.14694\/EdBook_AM.2013.33.393","article-title":"Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapies","author":"Long","year":"2013","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"11","key":"10.1016\/j.jocn.2019.12.063_b0090","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jocn.2019.12.063_b0095","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.2011.38.0527","article-title":"Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases","volume":"30","author":"Sperduto","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jocn.2019.12.063_b0100","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/bjc.2015.357","article-title":"The melanoma-specific graded prognostic assessment does not adequately discriminate prognosis in a modern population with brain metastases from malignant melanoma","volume":"113","author":"Wilkins","year":"2015","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.jocn.2019.12.063_b0105","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1001\/jamaoncol.2015.1206","article-title":"Clinical management of multiple melanoma brain metastases: a systematic review","volume":"1","author":"Goyal","year":"2015","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.jocn.2019.12.063_b0110","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.3892\/ijo.2015.2970","article-title":"Malignant melanoma brain metastases: treatment results and prognostic factors\u2013a single-center retrospective study","volume":"46","author":"Ostheimer","year":"2015","journal-title":"Int J Oncol"},{"issue":"7","key":"10.1016\/j.jocn.2019.12.063_b0115","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.2004.08.140","article-title":"Determinants of outcome in melanoma patients with cerebral metastases","volume":"22","author":"Fife","year":"2004","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jocn.2019.12.063_b0120","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1365-2133.2012.11039.x","article-title":"Up-to-date results on survival of patients with melanoma in Germany","volume":"167","author":"Eisemann","year":"2012","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jocn.2019.12.063_b0125","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3171\/jns.2000.93.1.0009","article-title":"Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients","volume":"93","author":"Wronski","year":"2000","journal-title":"J Neurosurg"},{"issue":"4","key":"10.1016\/j.jocn.2019.12.063_b0130","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0360-3016(96)00619-0","article-title":"Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials","volume":"37","author":"Gaspar","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jocn.2019.12.063_b0135","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.wneu.2017.05.131","article-title":"Outcome evaluation of patients with limited brain metastasis from malignant melanoma, treated with surgery, radiation therapy, and targeted therapy","volume":"105","author":"Pessina","year":"2017","journal-title":"World Neurosurg"},{"issue":"1","key":"10.1016\/j.jocn.2019.12.063_b0140","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0360-3016(92)90544-R","article-title":"Repopulation between radiation fractions in human melanoma xenografts","volume":"23","author":"Rofstad","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.jocn.2019.12.063_b0145","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2217\/fon.14.300","article-title":"Radiotherapy for cutaneous melanoma: current and future applications","volume":"11","author":"Gorayski","year":"2015","journal-title":"Future Oncol"},{"issue":"7547","key":"10.1016\/j.jocn.2019.12.063_b0150","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.jocn.2019.12.063_b0155","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","article-title":"Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial","volume":"10","author":"Chang","year":"2009","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jocn.2019.12.063_b0160","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jama.2016.9839","article-title":"Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial","volume":"316","author":"Brown","year":"2016","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jocn.2019.12.063_b0165","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(14)70061-0","article-title":"Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study","volume":"15","author":"Yamamoto","year":"2014","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jocn.2019.12.063_b0170","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.adro.2018.06.003","article-title":"Cognitive effects of stereotactic radiosurgery in adult patients with brain metastases: a systematic review","volume":"3","author":"Schimmel","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.jocn.2019.12.063_b0175","doi-asserted-by":"crossref","unstructured":"Ali MA et al. survival patterns of 5750 stereotactic radiosurgery-treated patients with brain metastasis as a function of the number of lesions. World Neurosurg, 2017. 107: p. 944\u201351 e1.","DOI":"10.1016\/j.wneu.2017.07.062"},{"issue":"6892","key":"10.1016\/j.jocn.2019.12.063_b0180","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.jocn.2019.12.063_b0185","doi-asserted-by":"crossref","first-page":"11","DOI":"10.12703\/P5-11","article-title":"BRAF inhibitors in clinical oncology","volume":"5","author":"Morris","year":"2013","journal-title":"F1000Prime Rep"},{"issue":"3","key":"10.1016\/j.jocn.2019.12.063_b0190","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/annonc\/mdv622","article-title":"Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy","volume":"27","author":"Ahmed","year":"2016","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.jocn.2019.12.063_b0195","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s40265-015-0442-6","article-title":"Nivolumab: a review in advanced melanoma","volume":"75","author":"Scott","year":"2015","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.jocn.2019.12.063_b0200","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ejso.2016.07.014","article-title":"Immunotherapy of melanoma","volume":"43","author":"Kee","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"10","key":"10.1016\/j.jocn.2019.12.063_b0205","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jocn.2019.12.063_b0210","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/cam4.1001","article-title":"A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanoma","volume":"6","author":"da Silveira Nogueira Lima","year":"2017","journal-title":"Cancer Med"},{"issue":"8","key":"10.1016\/j.jocn.2019.12.063_b0215","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jocn.2019.12.063_b0220","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.jocn.2019.12.063_b0225","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1200\/JCO.2013.49.8691","article-title":"Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma","volume":"31","author":"Ascierto","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9829","key":"10.1016\/j.jocn.2019.12.063_b0230","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial","volume":"379","author":"Falchook","year":"2012","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.jocn.2019.12.063_b0235","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jocn.2019.12.063_b0240","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586818322343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586818322343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:22:22Z","timestamp":1760822542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586818322343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":48,"alternative-id":["S0967586818322343"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2019.12.063","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metastatic melanoma: Surgical treatment of brain metastases \u2013 Analysis of 110 patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2019.12.063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}